• Home  / 
  • Blog  / 
  • Diabetes
  •  /  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

By electricdiet / January 13, 2021

Article Information

Acknowledgments. The authors thank the conference participants, who aside from the authors of this article included: Amanda Adler, MD, PhD, Oxford, U.K.; Maryam Afkarian, MD, PhD, Sacramento, CA; Radica Alicic, MD, Spokane, WA; Meaghan Allain, Falls Church, VA; Pamela Anderson, MBA, Titusville, NJ; George Bakris, MD, Chicago, IL; Petter Bjornstad, MD, Aurora, CO; Jaime Blais, PhD, Titusville, NJ; Glenn Chertow, MD, MPH, Palo Alto, CA; Alfred Cheung, MD, Salt Lake City, UT; Mihye (Mia) Cmiel, PharmD, Philadelphia, PA; Stephanie Cogan, New York, NY; Mark Cooper, MBBS, PhD, Melbourne, Australia; Kerry Cooper, MD, Gaithersburg, MD; Ian de Boer, MD, MS, Seattle, WA; Luca De Nicola, MD, PhD, Naples, Italy; Ralph Defronzo, MD, San Antonio, TX; Tony Deluzio, Bridgewater, NJ; Barbara Gillespie, MD, MMS, Chapel Hill, NC; Anthony Gucciardo, New York, NY; Michelle Hangey, BBA, MBA, Philadelphia, PA; Raymond Harris, MD, Nashville, TN; Sibylle Hauske, MD, MBA, Ridgefield, CT; Richard Haynes, DM, MRCP, Oxford, U.K.; Will Herrington, MA, MBBS, MD, Oxford, U.K.; Donna Hodge, Titusville, NJ; Diana Jalal, MD, Iowa City, IA; Meg Jardine, MBBS, PhD, Sydney, Australia; Nichole Jefferson, Dallas, TX; Steven Kahn, MBChB, Seattle, WA; Mikhail Kosiborod, MD, Kansas City, MO; Liz Leff, New York, NY; Kerry Leigh, RN, Washington DC; Helen Looker, MBBS, MRCP, Phoenix, AZ; Julie Lovshin, MD, PhD, Ontario, Canada; Sally Marshall, MD, Tyne, U.K.; Julie Maurey, PharmD, Philadelphia, PA; Peter McCullough, MD, MPH, Dallas, TX; Jim McDermott, PhD, Gaithersburg, MD; Ciaran McMullan, MB BCh, MMSc, Philadelphia, PA; Elizabeth Montgomery, New York, NY; Marcel H. Muskiet, MD, Amsterdam, the Netherlands; Robert Nelson, MD, PhD, Phoenix, AZ; Joshua Neumiller, PharmD, Pullman, WA; Susanne Nicholas, MD, MPH, PhD, Los Angeles, CA; Gregorio Obrador, MD, MPH, Mexico City, Mexico; Milton Packer, MD, Dallas, TX; Sachin Paranjape, PhD, Bridgewater, NJ; Meda Pavkov, MD, PhD, Atlanta, GA; Pablo Pergola, MD, PhD, San Antonio, TX; Michaela Petrini, PA-C, MHS, Ridgefield, CT; Glenda Roberts, Seattle, WA; Motoaki Sano, MD, PhD, Tokyo, Japan; Jay Shubrook, DO, Vallejo, CA; Anna Solini, MD, PhD, Pisa, Italy; Christopher Sorli, MD, PhD, Bridgewater, NJ; Paul Strumph, MD, Durham, NC; Merlin Thomas, MBChB, PhD, Melbourne, Australia; Aliza Thompson, MD, Silver Spring, MD; Marcello Tonelli, MD, Edmonton, Alberta, Canada; Robert Toto, MD, Dallas, TX; Daniel van Raalte, MD, PhD, Amsterdam, the Netherlands; Joseph Vassalotti, MD, New York, NY; Mark West, PharmD, Pittsburgh, PA; Ernest W. Wright, PhD, DSci, FRS, Los Angeles, CA; Jason Wright, PharmD, Gaithersburg, MD; and Helen Yeh, PhD, Gaithersburg, MD. The authors thank Emily J. Cox, PhD (Providence Health Care, Providence Medical Research Center, Spokane, WA) who assisted in the development of Fig 3.

Support. The following companies provided a grant to the NKF to support the planning and conduct of the workshop: AstraZeneca, Boehringer Ingelheim, Janssen, Sanofi, Merck, and Metavant.

The workshop sponsors had no role in the development of the workshop agenda or objectives. The sponsors were restricted from viewing any part of the workshop report manuscript until it was accepted for publication and therefore had no role in the content developed for this report.

Financial Disclosure. K.R.T. is supported by National Institutes of Health (NIH) grants and a Centers for Disease Control and Prevention contract and has served as a consultant for Eli Lilly & Co, Boehringer Ingelheim, AstraZeneca, Gilead, Goldfinch Bio, Novo Nordisk, Bayer, and Janssen. M.A.C. has received research support (nonsalary) from Amgen, AstraZeneca, Bristol Myers Squibb, Chiesi, CSL Behring, GlaxoSmithKline, and Novartis; research support (salary) from Novo Nordisk; and consulting fees from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Edwards Lifesciences, and Merck. L.P. has received personal fees from speaking and/or consulting from Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Janssen, Merck, and UpToDate. V.V. reports grants from the NIH and has served as a consultant and received honoraria from Bayer, Boehringer Ingelheim, Eli Lilly & Co, Janssen Pharmaceutical, Merck, and Retrophin and grant support for investigator-initiated research from AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius, and Janssen Pharmaceutical. P.R. reports having given lectures for AstraZeneca, Bayer, Novo Nordisk, and Boehringer Ingelheim and has served as a consultant for AbbVie, AstraZeneca, Bayer, Eli Lilly & Co, Boehringer Ingelheim, Astellas, Gilead, Mundipharma, Vifor, and Novo Nordisk, all fees given to Steno Diabetes Center Copenhagen. F.C.B. reports grants from the NIH and the Juvenile Diabetes Research Foundation; the University of Michigan has contracted with Gilead for his consulting services. P.F. reports receiving personal fees for advisory boards or scientific presentations from AstraZeneca, Mundipharma, Boehringer Ingelheim, Eli Lilly & Co, and Novartis. K.J.F. is a consultant for Responsum Health, Bayer, Gilead, Chiesi, Talaris, Retrophin, Otsuka, and Veloxis. H.J.L.H. has served as a consultant for Abbvie, AstraZeneca, Boehringer Ingelheim, Fresenius, Gilead, Janssen, Merck, Mundipharma, Mitsubishi-Tanabe, and Retrophin and received grant support from Abbvie, AstraZeneca, Boehringer Ingelheim, and Janssen. A.K.M. has contracts with Aurinia, Boehringer Ingelheim, Calliditas, Duke Clinical Research Institute, and Pfizer; has been a member of the scientific advisory board for AstraZeneca; and has consultancy agreements with Proteomics Int. S.E.R. reports grants from the NIH, Bayer, and Ironwood Pharmaceuticals and has participated in advisory boards for Reata and Bayer Healthcare. M.E.M. reports grants from the National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Novartis, and Novo Nordisk and consulting fees from Merck, Pfizer, and Janssen. D.K.M. has received honoraria for clinical trial leadership from AstraZeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Lexicon, Eisai Inc, GlaxoSmithKline, Lilly USA, and Esperion and honoraria for consultancy from AstraZeneca, Sanofi Aventis, Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Metavant, Applied Therapeutics, and Afimmune. C.W. has received honoraria from AstraZeneca, Sanofi, Boehringer Ingelheim, Merck, Eli Lilly & Co, and Mundipharma. T.M. is employed by the NKF. V.P. has received fees for advisory boards, steering committee roles, or scientific presentations from Abbvie, Astellas, AstraZeneca, Bayer, Baxter, BMS, Boehringer Ingelheim, Chinook, Dimerix, Durect, Eli Lilly & Co, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Retrophin, Sanofi, Servier, Vifor, and Tricida.

Sell Unused Diabetic Strips Today!

About the author